Tirofiban
Aggrastat (tirofiban) is a small molecule pharmaceutical. Tirofiban was first approved as Aggrastat on 1998-05-14. It is used to treat coronary disease, myocardial infarction, and unstable angina in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Aggrastat (generic drugs available since 2021-04-08)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aggrastat | New Drug Application | 2023-01-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| coronary disease | — | D003327 | — |
| myocardial infarction | EFO_0000612 | D009203 | I21 |
| unstable angina | EFO_1000985 | D000789 | I20.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Tirofiban Hydrochloride, Aggrastat, Medicure | |||
| 6770660 | 2023-05-01 | U-1444 | |
HCPCS
Code | Description |
|---|---|
| G9531 | Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar |
| J3246 | Injection, tirofiban hcl, 0.25 mg |
Clinical
Clinical Trials
352 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 13 | 43 | 104 | 84 | 39 | 279 |
| Asthma | D001249 | EFO_0000270 | J45 | 2 | 12 | 17 | 7 | 7 | 44 |
| Healthy volunteers/patients | — | 19 | — | — | 1 | 1 | 21 | ||
| Emphysema | D004646 | EFO_0000464 | J43 | — | — | — | 2 | 1 | 3 |
| Disease progression | D018450 | — | — | — | 1 | 1 | 2 | ||
| Chronic bronchitis | D029481 | J42 | 1 | — | — | 1 | — | 2 | |
| Bronchiectasis | D001987 | HP_0002110 | J47 | — | — | — | 1 | — | 1 |
| Respiratory sounds | D012135 | HP_0010307 | R06.1 | — | — | — | 1 | — | 1 |
| Airway obstruction | D000402 | — | — | — | 1 | — | 1 | ||
| Pulmonary emphysema | D011656 | J43 | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | 1 | 1 | — | — | 3 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | 1 | 2 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spinal cord injuries | D013119 | EFO_1001919 | 1 | 1 | — | — | — | 2 | |
| Non-small-cell lung carcinoma | D002289 | — | 1 | — | — | — | 1 | ||
| Dyspnea | D004417 | HP_0002094 | R06.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Bronchial hyperreactivity | D016535 | — | — | — | — | 1 | 1 | ||
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
| Smoking | D012907 | EFO_0003768 | F17 | — | — | — | — | 1 | 1 |
| Airway remodeling | D056151 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TIROFIBAN |
| INN | tirofiban |
| Description | Tirofiban is a member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group. It has a role as a fibrin modulating drug, a platelet glycoprotein-IIb/IIIa receptor antagonist and an anticoagulant. It is a member of piperidines, a sulfonamide and a L-tyrosine derivative. |
| Classification | Small molecule |
| Drug class | fibrinogen receptor antagonists (glycoprotein IIb/IIIa receptor antagonists) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 144494-65-5 |
| RxCUI | 73137 |
| ChEMBL ID | CHEMBL916 |
| ChEBI ID | 9605 |
| PubChem CID | 60947 |
| DrugBank | DB00775 |
| UNII ID | GGX234SI5H (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Aggrastat - SciClone Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,912 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
86,647 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more